3 results about "Secretin" patented technology

The invention relates to the use of a probiotic composition comprising a lactic acid producing bacterial strain, a conditioned medium or microvesicles from the lactic acid producing bacterial strain in treatment or prevention of hyposecretinemia. The lactic acid producing bacterial strain, the conditioned medium and / or the microvesicles is or are capable of inducing release, and optionally production, of secretin locally in a gastrointestinal tract of a subject suffering from hyposecretinemia or having a risk of suffering from hyposecretinemia. The invention also relates to screening of lactic acid producing bacterial strains suitable in treatment or prevention of hyposecretinemia. Secretin

The present invention relates to selective GLP1R agonists. In particular, the present invention relates to the finding that the secretin (SCT) may be converted into highly potent and selective GLP1R agonists.

This invention relates to the application of secretin in the preparation of drugs for treating steatohepatitis associated with metabolic dysfunction, belonging to the field of biomedical technology. This invention provides the application of secretin in the preparation of drugs for treating steatohepatitis associated with metabolic dysfunction. Cell model, gene knockout, in vivo complementation, and exogenous protein intervention experiments were conducted, revealing that secretin has significant in vitro and in vivo protective effects against steatohepatitis associated with metabolic dysfunction. In vitro, secretin can significantly improve oleic acid-induced lipid accumulation in hepatocytes, inhibit abnormal accumulation of lipid droplets in hepatocytes, reduce the expression of inflammatory factors in hepatocytes, alleviate hepatocyte inflammatory damage caused by lipotoxicity, and enter hepatocytes through endocytosis. It can alleviate high-fat diet-induced hepatic steatosis and inflammatory infiltration in MASH mice, and reduce the degree of liver fibrosis.